Affibody and Inmagene autoimmune partnership completes regulatory milestone 09-Mar-2021 By Jane Byrne Affibody and Inmagene Biopharmaceuticals report that the US FDA has cleared the interleukin-17 (IL-17) blocker, izokibep, to proceed to phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis.